Traws Pharma, Inc.(TRAW) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results · COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of clinical rebound and good overall tolerability · Flu: Phase 1 pharmacokinetic profile supports the potential for tivoxavir marboxil to be a one-time treatment for flu, including pandemic and avian flu, with good overall tolera ...